# US 2026/0097025 A1 · Amlodipine formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097025 A1
- Document ID: US20260097025A1
- Status: Published application
- Kind: A1
- Application number: 19/240,194
- Filed: 2025-06-17
- Published: 2026-04-09
- Earliest claimed: 2016-10-07
- Assignees: Azurity Pharmaceuticals, Inc.
- Applicants: Azurity Pharmaceuticals, Inc.
- Inventors: Scott BRAUER; Gerold L. MOSHER
- Web page: https://patentgrep.com/patent/US20260097025A1

## CPC

- A61K 31/4422: 1,4-Dihydropyridines, e.g. nifedipine, nicardipine
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/10: Dispersions; Emulsions
- A61K 47/02: Inorganic compounds
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 9/12: Antihypertensives
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are stable amlodipine oral liquid formulations. Also provided herein are methods of using amlodipine oral liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).

## Claims

### Claim at position 1

1-30. (canceled)

### Claim 31

An oral liquid formulation comprises:
(i) amlodipine benzoate in an amount corresponding to 1.0 mg/ml amlodipine freebase;
(ii) 0.2 mg/ml to 10 mg/ml of sodium benzoate;
(iii) a suspension aid comprising silicon dioxide, hydroxypropyl methylcellulose, methylcellulose, microcrystalline cellulose, carboxymethyl cellulose sodium, polyvinylpyrrolidone, xanthan gum, or any combination thereof;
(iv) a non-ionic surfactant that is present at about 0.1 mg/ml to about 3.0 mg/ml in the oral liquid formulation;
(v) optionally one or more selected from a buffer, a flavoring agent, a sweetener, a preservative; and
(vi) water;
wherein the oral liquid formulation is stable at 5±5° C. for a storage period of at least 12 months; and wherein the stable oral liquid formulation has 95% w/w or greater of the initial amlodipine amount and 5% w/w or less total impurities or related substances at the end of the given storage period.

### Claim 32 (depends on 31)

The formulation of claim 31, wherein the suspension aid is present in the oral liquid formulation at 5.0 mg/ml to 15.0 mg/ml.

### Claim 33 (depends on 32)

The formulation of claim 32, wherein the suspension aid is present in the oral liquid formulation at 3.0 mg/ml to 10.0 mg/ml.

### Claim 34 (depends on 31)

The formulation of claim 31, wherein the suspension aid comprises silicon dioxide, hydroxypropyl methylcellulose, microcrystalline cellulose, carboxymethyl cellulose sodium, or any combination thereof.

### Claim 35 (depends on 31)

The formulation of claim 31, wherein the suspension aid comprises silicon dioxide and hydroxypropyl methylcellulose.

### Claim 36 (depends on 31)

The formulation of claim 31, wherein the non-ionic surfactant is present at about 1.0 mg/ml in the oral liquid formulation.

### Claim 37 (depends on 31)

The formulation of claim 31, wherein the non-ionic surfactant is polyoxyethylene glycol sorbitan alkyl ester.

### Claim 38 (depends on 37)

The formulation of claim 37, wherein the polyoxyethylene glycol sorbitan alkyl ester is polysorbate 20 or polysorbate 80.

### Claim 39 (depends on 31)

The formulation of claim 31, wherein the non-ionic surfactant is a block copolymers of polyethylene glycol and polypropylene glycol, a polyethylene glycol octylphenyl ether, polyethylene glycol alkyl ether, or any combination thereof.

### Claim 40 (depends on 31)

The formulation of claim 31, wherein the pH is between 4 and 6.

### Claim 41 (depends on 31)

The formulation of claim 31, wherein the oral liquid formulation comprises a buffer.

### Claim 42 (depends on 41)

The formulation of claim 41, wherein the buffer is present at 0.1 mg/ml to about 1.0 mg/ml in the oral liquid formulation.

### Claim 43 (depends on 41)

The formulation of claim 41, wherein the buffer comprises a citrate buffer, a phosphate buffer, an acetate buffer, or any combination thereof.

### Claim 44 (depends on 43)

The formulation of claim 43, wherein the citrate buffer comprises critic acid and sodium citrate.

### Claim 45 (depends on 31)

The formulation of claim 31, wherein the oral liquid formulation comprises a sweetener.

### Claim 46 (depends on 45)

The formulation of claim 45, wherein the sweetener is present in about 0.5 mg/ml to about 0.9 mg/ml in the oral liquid formulation.

### Claim 47 (depends on 45)

The formulation of claim 45, wherein the sweetener comprises glucose, fructose, sucrose, xylitol, tagatose, sucralose, maltitol, isomaltulose, hydrogenated isomaltulose, lactitol, sorbitol, erythritol, trehalose, maltodextrin, or any combination thereof.

### Claim 48 (depends on 47)

The formulation of claim 47, wherein the sweetener is sucralose.

### Claim 49 (depends on 31)

The formulation of claim 31, wherein the oral liquid formulation comprises a flavoring agent.

### Claim 50 (depends on 31)

The formulation of claim 31, wherein the oral liquid formulation is in the form of a suspension.
